HeartWare International Acquires Valtech Cardio
By HospiMedica International staff writers Posted on 03 Sep 2015 |
Image: The Cardioband direct annuloplasty system (Photo courtesy of Valtech Cardio).
Medical device developer HeartWare International (Framingham, MA, USA) has bought medical startup Valtech Cardio (Or Yehuda, Israel), developer of a novel heart valve repair and replacement technology, for an estimated USD 920 million in stock.
HeartWare International is a leading innovator of miniaturized circulatory support technologies, such as ventricular assist devices (VADs), which are revolutionizing the treatment of advanced heart failure (HF). The acquisition of Valtech Cardio, which specializes in surgical and transcatheter valve repair and replacement devices for the treatment of mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR), will provide HeartWare with multiple commercial opportunities in the significantly underserved areas of mitral and tricuspid valve diseases, from which many VAD patients suffer.
HeartWare will benefit from a wide technology portfolio, including Cardioband, an interventional, transfemoral, direct annuloplasty system designed for MR and TR repair; CardioValve, a transseptally delivered, low-profile, transcatheter mitral valve replacement (TMVR) system with five degrees of steering maneuverability; Cardinal, a semi-rigid, adjustable, annuloplasty ring system that enables fine-tuning of the ring diameter and leaflet coaptation on a beating heart; and V-Chordal, a surgical and interventional chord replacement system for noninvasive MR repair.
“Valtech provides HeartWare with commercial-stage products for mitral repair, as well as a robust technology pipeline, an advanced R&D center and an impressive, experienced team with a proven track record,” said Doug Godshall, CEO of HeartWare International. “This combination represents an attractive opportunity for value creation for HeartWare shareholders, customers, employees, and patients by expanding HeartWare's footprint in the high-growth structural heart market.”
“By joining HeartWare, we can more quickly and fully realize the potential of our pipeline technologies and further influence the underpenetrated markets that we serve,” said Amir Gross, Founder and CEO of Valtech. “Together, we can offer clinical heart failure teams a compelling portfolio of surgical and interventional technologies to serve the advanced heart failure population.”
Related Links:
HeartWare International
Valtech Cardio
HeartWare International is a leading innovator of miniaturized circulatory support technologies, such as ventricular assist devices (VADs), which are revolutionizing the treatment of advanced heart failure (HF). The acquisition of Valtech Cardio, which specializes in surgical and transcatheter valve repair and replacement devices for the treatment of mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR), will provide HeartWare with multiple commercial opportunities in the significantly underserved areas of mitral and tricuspid valve diseases, from which many VAD patients suffer.
HeartWare will benefit from a wide technology portfolio, including Cardioband, an interventional, transfemoral, direct annuloplasty system designed for MR and TR repair; CardioValve, a transseptally delivered, low-profile, transcatheter mitral valve replacement (TMVR) system with five degrees of steering maneuverability; Cardinal, a semi-rigid, adjustable, annuloplasty ring system that enables fine-tuning of the ring diameter and leaflet coaptation on a beating heart; and V-Chordal, a surgical and interventional chord replacement system for noninvasive MR repair.
“Valtech provides HeartWare with commercial-stage products for mitral repair, as well as a robust technology pipeline, an advanced R&D center and an impressive, experienced team with a proven track record,” said Doug Godshall, CEO of HeartWare International. “This combination represents an attractive opportunity for value creation for HeartWare shareholders, customers, employees, and patients by expanding HeartWare's footprint in the high-growth structural heart market.”
“By joining HeartWare, we can more quickly and fully realize the potential of our pipeline technologies and further influence the underpenetrated markets that we serve,” said Amir Gross, Founder and CEO of Valtech. “Together, we can offer clinical heart failure teams a compelling portfolio of surgical and interventional technologies to serve the advanced heart failure population.”
Related Links:
HeartWare International
Valtech Cardio
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures